VERDESO
LOE ApproachingNDATOPICALAEROSOL, FOAM
Approved
Sep 2006
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERDESO is a topical aerosol foam formulation approved by the FDA in 2006 for dermatological conditions. The exact indication and mechanism of action are not specified in available data, but the topical route and foam delivery suggest treatment of skin conditions requiring localized application. This is a small-molecule NDA product sponsored by Almirall.
$0.032BPart D
LOE Approaching1.0 years to LOEProduct is approaching loss of exclusivity with minimal current Medicare Part D volume, suggesting a small, declining team focused on portfolio management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on VERDESO at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.